Table 4 Association between VEGFR2 rs2239702 and VEGF rs1570360 polymorphisms and the PFS of the patients.

From: The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma

VEGFR2

Progression

All patients

MST *

Log-rank P

Rs2239702

 GG

19

39

43.2

0.031

 AG

28

34

22.5

 

 AA

20

27

25.2

 

 GG

19

39

43.2

0.008

 AG + AA

48

61

24.5

 

VEGF Rs1570360

 GG

49

78

33.4

0.032

 AG

13

17

20.33

 

 AA

5

5

4

 

 GG

49

78

33.4

0.034

 AG + AA

18

22

18.2

 
  1. *Mean survival time.
Back to article page